Next Article in Journal
Targeted Delivery of Personalized Cancer Vaccines Based on Antibody–Antigen Complexes
Previous Article in Journal
Beyond Vaccination: Exploring Young Adults’ Awareness, Knowledge, and Attitudes Related to Sexually Transmitted Infections in Romania
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Vaccines
Volume 13
Issue 3
10.3390/vaccines13030323
vaccines-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Cost-Effectiveness of Adjuvanted Influenza Vaccine Compared with Standard and High-Dose Influenza Vaccines for Persons Aged ≥50 Years in Spain

by
Alberto Perez-Rubio
1,
Roberto Flores
2,
Jesus Ruiz Aragon
3,
Javier Sanchez
4,
Sergio Marquez-Peláez
5,
Piedad Alvarez
6,
Andres Osorio Muriel
7 and
Joaquin Mould-Quevedo
8,*
1
Hospital Clínico Universitario de Valladolid, 47003 Valladolid, Spain
2
Medical Scientific Liaison, CSL Seqirus, 08027 Barcelona, Spain
3
Hospital Universitario Puerta del Mar, 11009 Cádiz, Spain
4
Modeling and Simulation, Evidera, Torre Nozar, Titan, 15, 28045 Madrid, Spain
5
Department of Economics, Economic Analysis, Faculty of Business Pablo de Olavide University, 41013 Seville, Spain
6
Evidence, Modeling, and Synthesis, Evidera, 500 Totten Pond Road, Waltham, MA 02451, USA
7
Modeling and Simulation, Evidera, Bogota CO Calle 90, Bogota 110221, Colombia
8
Global Health Economics, CSL Seqirus, Summit, NJ 07901, USA
*
Author to whom correspondence should be addressed.
Vaccines 2025, 13(3), 323; https://doi.org/10.3390/vaccines13030323
Submission received: 22 January 2025 / Revised: 28 February 2025 / Accepted: 12 March 2025 / Published: 19 March 2025
Browse Figures
Versions Notes

Abstract

:
Background: The prevalence of chronic conditions that increase the risk of influenza complications is high among individuals aged ≥50 years, and evidence suggests age-related changes in immune responses to vaccines begin to decline at this age. Persons aged 50–59 years have high rates of influenza infections and are also the most likely age group to be employed. Thus, the burden of influenza is high in this age group. Methods: We investigated the cost-effectiveness of vaccination with an adjuvanted quadrivalent influenza vaccine (aQIV) in a Spanish population aged ≥50 years at high risk of influenza complications. Using a static decision-tree model specifically designed to analyze Spanish data, we calculated incremental cost-effectiveness ratios (ICERs) for aQIV vs. egg-based QIV (QIVe; indicated for any age) and aQIV vs. high-dose QIV (HD-QIV; indicated for persons aged ≥60 years) from payer and societal perspectives. We compared ICERs against a willingness-to-pay threshold of EUR 25,000 per quality-adjusted life year (QALY) gained. The impact of input uncertainty on ICER was evaluated through a probabilistic sensitivity analysis (PSA) and a one-way deterministic sensitivity analysis (DSA). Results: The total incremental cost of vaccination with aQIV was EUR –86,591,967.67, which was associated with gains of 241.02 in QALY (EUR –359,268.05 per QALY gained) and 318.04 in life years (EUR −272,271.37 per life year gain). Compared with the willingness-to-pay threshold of EUR 25,000 per QALY gained, aQIV was the most cost-effective influenza vaccine relative to the combination of QIVe or HD-QIV. These findings were supported by PSA and DSA analyses. Conclusions: In the model, aQIV dominated QIVe and HD-QIV, demonstrating that aQIV use would be cost-saving for persons aged ≥50 years who are at high risk of influenza complications.

1. Introduction

Since the global impact of the coronavirus disease 2019 (COVID-19) pandemic has begun to wane, influenza has resumed its place as a leading cause of hospitalizations and deaths worldwide in the 2023–2024 influenza season [1,2]. Historically, seasonal influenza was associated with 13% of all respiratory disease deaths per year, in association with 1 billion influenza cases annually [3,4]. Similarly to other countries, the costs of influenza in Spain are high, amounting to EUR 1 billion per year in direct medical costs and indirect costs such as absences from work due to influenza illness or caring for family members with the disease [5].
Rates of hospitalizations and mortality are highest among those aged ≥65 years [6,7,8,9]. Persons aged ≥50 years have the highest rates of influenza infections [10]. Out of all age groups, those aged 50–59 years have the highest rate of employment in Spain [11], and thus absences due to their own or a family member’s illness can have a major impact on the overall burden of influenza [10,12]. The prevalence of chronic, cardiometabolic diseases, which increase the risk of influenza complications, is also high in adults aged ≥50 years [13,14,15,16], potentially contributing to increased influenza severity and the costs of medical care in this age group [12]. In addition, age-related changes in immune function that reduce immune responses to vaccination (known as immunosenescence) may begin as early as age 50 years [17,18].
Annual influenza vaccination is recommended in Spain for adults aged ≥60 years as well as younger persons at high risk of influenza complications due to chronic diseases and other medical conditions [19]. Currently, the population younger than 60 years of age may be given a standard-dose, non-adjuvanted egg-based influenza vaccine containing 15 μg of hemagglutinin from each of the influenza virus strains contained within the vaccine. Two vaccines specifically developed to overcome age-related decreases in immune response are authorized for use in older adults [19,20]. The adjuvanted influenza vaccine contains the MF59® adjuvant in addition to the standard 15 μg dose of hemagglutinin for each influenza strain in the vaccine and is authorized for persons aged ≥65 years. In older adults, the MF59 adjuvant produces broader, more robust, and more durable immune responses compared with the standard influenza vaccine [21,22]. MF59-adjuvanted influenza vaccines have also been shown to provide greater immunogenicity against both homologous and heterologous influenza strains vs. standard vaccines in persons younger than 65 years [23]. In addition, a high-dose influenza vaccine, containing 60 μg of hemagglutinin for each selected influenza virus, is authorized for individuals aged ≥60 years [19]. In this population, the high-dose vaccine produces a stronger immune response relative to standard influenza vaccines [24].
In Spain, persons aged 50–59 years, including those at high risk of influenza complications, typically receive standard-dose influenza vaccine. Because of the excess burden of influenza in this population, we sought to investigate the cost-effectiveness of adjuvanted influenza vaccine in high-risk persons aged 50–59 as well as adults aged ≥60 years.

2. Materials and Methods

2.1. Model Design

The health economic model used in this study was based on a static decision-tree model designed for use in Spain according to Spanish best practices for health economic modeling [25,26]. Similar models have been used for influenza vaccine cost-effectiveness analyses in other countries [27,28,29,30,31], while previous studies have used the Spanish model to estimate health economic endpoints related to influenza vaccination in Spain among children and adults aged ≥9 years at risk of influenza complications and among older adults aged ≥65 years [26,32,33,34,35]. In this analysis, we used the model to simulate the costs and burden of influenza disease and the costs and benefits of influenza vaccination with the adjuvanted quadrivalent influenza vaccine (aQIV), the egg-based quadrivalent influenza vaccine (QIVe), or the high-dose quadrivalent influenza vaccine (HD-QIV) among residents of Spain aged ≥50 years during a single influenza season.

2.2. Model Inputs and Calculations

Figure 1 displays a schematic of the model inputs. The Spanish population aged ≥50 years was divided into the following age groups: 50–59, 60–64, 65–74, and ≥75 years, which were further divided into subgroups based on high or low risk of influenza complications (Table 1). All individuals aged ≥60 years were included in the high-risk group.
The model analysis focused on the high-risk population and excluded persons aged 50–59 years at low risk of influenza complications. In the model, those aged ≥50 years were either vaccinated or unvaccinated. Based on vaccination coverage rates for each age group, vaccinated individuals were divided into two comparator arms, one where they received either a QIVe or an HD-QIV according to their age group indication (50–59 or ≥60 years, respectively) and another arm where all people aged ≥50 years received an aQIV. Over a one-year time horizon representing a single influenza season, the vaccinated and unvaccinated populations were divided into the following subgroups: uninfected or asymptomatic; symptomatic cases not seeking medical support; or symptomatic cases requiring either a primary care visit, emergency department visit, or hospitalization. Each subgroup was assigned a fixed cost and disutility associated value, and hospitalized patients were assigned a probability of death. The totals for each cohort for the entire influenza season were calculated by aggregating the outcomes and costs (direct medical and societal) across the different subgroups. All costs are expressed in 2024 euros. Following Spanish cost-effectiveness guidelines, productivity loss due to death and quality-adjusted life year (QALY) loss due to death were calculated over a lifetime horizon and discounted at 3% per year [25]. The incidence of influenza cases per 100,000 Spanish residents over seven influenza seasons (2013–2020) was based on data from the Instituto de Salud Carlos III Centro Nacional de Microbiología (ISCIII) (Table S1) [39,40,41,42,43,44,45]. Mortality data over the same time period appear in Table S2 [46]. Table 2 lists inputs used in the model, and Table S3 shows the population estimates on which employment-related figures in Table 2 are based. Table S4 provides the basis for the population of older adults requiring care by a family member. The tender price of QIVe used in the model was based on the weighted average of the prices in each region (Table S5).
The base case relative vaccine effectiveness (rVE) estimate for the aQIV vs. the HD-QIV was 1.40% (95% confidence interval [CI], −1.7% to 4.4%), based on a 2022 meta-analysis of head-to-head vaccine studies conducted in the ≥65 years of age population [78]. This rVE estimate is consistent with values determined in multiple real-world evidence studies, including test-negative design studies comparing the effectiveness of the aQIV vs. the HD-QIV for the prevention of laboratory-confirmed influenza cases [79,80,81,82,83,84,85,86]. We assumed the rVE was the same (1.40%) for the 60–64 year age group. The rVE used in the base case was in line with the first randomized study between the aQIV and the HD-QIV, which demonstrated that the two vaccines did not differ in effectiveness against laboratory-confirmed influenza [87]. For the aQIV vs. the QIVe, the base case rVE was 20.0% (95% CI, 2–34%) in the ≥65 year age group [88], and we assumed the same benefit would exist for those aged 50–59 years as no rVE estimates for the aQIV vs. the QIVe in persons younger than 64 years have yet been published.

2.3. Analysis

The model outputs include costs, burden of illness (symptomatic cases, primary care visits, emergency department [ED] visits, hospitalizations, and deaths in persons vaccinated with the aQIV or their age-indicated vaccine [QIVe or HD-QIV]), and incremental analysis. Costs comprised public health system costs, discounted societal costs, and total discounted QALYs. Public payer costs were not discounted because they were calculated over only one year, whereas societal costs and QALY losses due to death were calculated based on life expectancy and discounted accordingly. Incremental cost-effectiveness ratios (ICERs) for the aQIV vs. the QIVe or the HD-QIV were calculated from a direct medical payer and societal perspective.
ICERs were also compared against a willingness-to-pay threshold of EUR 25,000 per QALY gained, which is the cost-effectiveness range used by the National Health Service in Spain [89,90]. To assess the effect of uncertainty on the ICERs, a probabilistic sensitivity analysis (PSA) was conducted in which parameters were varied based on their CIs over 10,000 iterations of the model. A one-way deterministic sensitivity analysis (DSA) was also used to evaluate the impact of input uncertainty on ICER. Finally, a second sensitivity analysis was conducted using 13 alternative modeling scenarios involving different cost and benefit discount rates, the rates of influenza vaccine coverage among high- and low-risk groups, the types of influenza vaccines used in different age groups, and the costs of the QIVe (Table S6). In addition, the alternative scenarios included rVEs for the aQIV vs. the HD-QIV that utilized age group–specific estimates from the Domnich et al. meta-analysis (7.8% for ages 60–64 and 65–74 years and 12.5% for ≥75 years) [78] and lower (13.9%) [91] and higher values (34.6%) [92] for the rVE of the aQIV vs. the QIVe (Table S6).

3. Results

As shown in Table 3, 9,094,819 individuals at high risk of influenza complications were vaccinated with either the QIVe or the HD-QIV (according to age-based indications) in the current scenario or with the aQIV in the alternative scenario of the model. In the 50–59 year age group, aQIV vaccination cost EUR 9.6 million more than QIVe vaccination, but costs of the aQIV were lower than costs of HD-QIV vaccination in all groups aged ≥60 years.
In the cost-effectiveness model analysis (Table 4), the aQIV dominated vaccines as currently indicated, resulting in reduced QALY and life years lost; fewer influenza cases, influenza-related outpatient and inpatient medical visits, and deaths; and lower direct medical costs related to influenza (Table 4). The total incremental savings of vaccination with the aQIV was EUR 86,591,967.67, which was associated with gains of 241.02 in QALY (EUR −359,268.05 per QALY gained) and 318.04 in life years (EUR −272,271.37 per life year gain).
The PSA confirmed that costs and QALY lost were lower with the aQIV than with the QIVe plus the HD-QIV across the range of 95% CI values for model parameters (Figure 2).
When compared against the willingness-to-pay threshold of EUR 25,000 per QALY gained, aQIV had a 100% probability of being the most cost-effective influenza vaccine relative to the combination of QIVe or HD-QIV (Figure 3).
In the DSA (Figure 4), vaccine costs were shown to have the greatest impact on ICER, followed by vaccine coverage in each high-risk age group, in descending order. Other parameters had relatively little effect on cost-effectiveness.
The results of the additional sensitivity analysis, testing the model with different inputs, generally supported the dominance of vaccination with the aQIV over vaccination with the QIVe or the HD-QIV in high-risk persons aged ≥50 years (Table S7). The aQIV was found to be more effective in all scenarios and dominant in terms of both cost and effectiveness in 10 of 13 scenarios (public health system perspective, discount rates of 0% and 1.5%, different vaccine coverage rates per Garcia et al. 2016 [75], QIVe and HD-QIV given to 50–59 and ≥75 year age groups, respectively, alternate rVE point estimates, and lower and higher prices for the QIVe).

4. Discussion

This modeling analysis is the first to estimate the cost-effectiveness of using the aQIV in persons aged ≥50 years in any country. The results support the use of the aQIV in persons aged 50–59 years, who would normally receive the QIVe, and those aged ≥60 years, who would receive the HD-QIV in Spain. Administration of the aQIV to the high-risk population reduced the incidence of symptomatic cases of influenza, inpatient and outpatient medical encounters, deaths, and all associated costs. These savings offset the higher tender price of the aQIV relative to the QIVe for the group aged 50–59 years and amplified the cost savings of the aQIV relative to the higher tender price for the HD-QIV for those aged ≥60 years.
In Spain, 72% of persons aged 50–64 years are employed [11]. Due to age and experience, many of these individuals may hold positions of seniority at their workplace, lending an outsized impact on their absence from work due to illness or the need to care for a family member. A systematic literature review has shown that influenza-associated indirect costs, including absenteeism due to either infection or caring for infected family members, are higher in the 50–64 year age group than in adults aged ≤50 years [12]. At the same time, the rates of chronic diseases such as obesity, diabetes, and cardiovascular disease, which increase the risk of influenza complications and death, begin to climb at age ~50 years, and half of middle-aged adults have at least two high-risk conditions [13,14,15,16]. In addition, immunosenescence begins to emerge after age 50 and will affect most individuals aged ≥60 years [17,18].
Despite the burden of influenza in the 50–64 year age group, many countries’ health authorities do not cover, or even recommend, influenza vaccination for persons younger than 60 or 65 years, particularly for healthy individuals. Yet multiple cost-effectiveness analyses conducted in both Northern and Southern Hemisphere nations support influenza vaccination for all persons 50–64 years, with the cost of vaccination falling well below cost-effectiveness thresholds from both payer and societal perspectives, even if the population is at low risk of influenza complications [93,94,95,96,97]. A recent analysis from the UK described the benefits of expanding vaccination with the cell-based quadrivalent influenza vaccine (QIVc) to low-risk persons aged 50–64 years. Using a dynamic transmission model calibrated to actual infection data from the UK, the authors showed that vaccinating this age group was cost-saving due to reductions in influenza disease costs [95]. Another modeling study demonstrated that vaccinating low-risk individuals between 50 and 64 years of age reduces burdens on the healthcare system, including bed usage in acute and intensive care wards [96].
Our modeling analysis focused on high-risk persons aged ≥50 years because the burdens of influenza are highest among these individuals. Previous modeling analyses conducted with the Spanish population aged ≥65 years have demonstrated the cost-effectiveness of strategies using adjuvanted influenza vaccines. One analysis showed that reductions in influenza-associated medical costs offset the price difference between the adjuvanted vaccine and the standard-dose vaccine [98], whereas another demonstrated that use of adjuvanted vaccines would lead to EUR 82 million in savings for Spanish health systems, with a cost–benefit ratio of 12.83 [99]. An analysis conducted in 2021 that compared the aQIV to the HD-QIV in persons aged ≥65 years demonstrated cost savings of EUR 64.2 million [32]. A dynamic model designed to account for herd immunity showed that the aQIV is more cost-effective than the QIVe in the ≥65 population [34]. In another recent analysis, the aQIV was likewise shown to be more cost-effective than the recombinant quadrivalent influenza vaccine (QIVr) [33]. Our findings are consistent with all of these studies and further demonstrate that these benefits are extended to high-risk persons aged 50–59 years. Another study published in 2021 that also analyzed the cost-utility between high-dose and adjuvanted vaccines concluded that HD-QIV use in persons aged ≥65 years was at least cost-effective, if not dominant, over the adjuvanted trivalent influenza vaccine (aTIV) in Spain [35]. However, this study has important limitations. In the absence of a clinical trial comparing the high-dose and adjuvanted vaccines, the authors used indirect comparisons from a clinical trial and meta-analysis of the HD-TIV vs. standard influenza vaccine over several seasons, along with a one-season observational study of the aTIV vs. a virosomal vaccine [24,100,101]. This indirect comparison resulted in an rVE that was not supported by a meta-analysis of head-to-head, real-world evidence (RWE) studies comparing the aTIV with the HD-TIV or standard influenza vaccines [78,91]. During the review of the current article, a new meta-analysis has been published that again concludes that no difference in benefit was observed between aQIV and HD-QIV [102]. Results from a recent randomized, head-to-head pragmatic trial of the HD-QIV vs. the aQIV with laboratory-confirmed influenza are consistent with the RWE meta-analysis [87].
When we conducted this analysis, no efficacy data from randomized controlled trials or effectiveness data from real-world studies were available for the aQIV in persons aged 50–64 years. Due to this limitation, we assumed that the rVE point estimates from studies in the ≥65-year-old population would be the same for the population aged 50–64 years. We also assumed hospitalization costs would be the same in all age groups. However, overall rates of influenza-related hospitalization are highest among adults aged ≥65 compared to all other age groups, whereas the costs of hospitalization for individuals aged 50–64 years are often higher on a per-case basis, possibly because middle-aged adults who require hospitalization for influenza have more severe complications [12]. Recently, the B/Yamagata influenza strain has disappeared from circulation [103]. Like some other health authorities, the Spanish Ministry of Health has recommended switching to trivalent formulations for influenza vaccines used in future seasons [19]. Our analysis focused on quadrivalent influenza vaccines, as recommended in recent seasons. It is unlikely the presence or absence of a fourth strain would have affected our results, as most prior studies have focused on trivalent vaccines. The change from quadrivalent to trivalent vaccines might, however, affect the analysis if the change to trivalent causes a price change, and the Spanish Medicines Agency must approve the new prices.

5. Conclusions

Our findings suggest that vaccinating the population aged ≥50 years against influenza in Spain will result in cost savings. In addition, we demonstrate the benefits of the aQIV in high-risk persons aged 50–59 years, who are normally eligible for the standard-dose QIVe. Vaccination with the aQIV vs. the QIVe reduces influenza disease burden, including symptomatic cases, outpatient medical visits, ED visits, hospitalizations, and deaths—as well as associated costs. These cost reductions more than offset the increased tender price of the aQIV relative to the QIV, supporting the cost-effectiveness of the aQIV for persons aged ≥50 years who are at high risk of influenza complications.

Supplementary Materials

The following supporting information can be downloaded at https://www.mdpi.com/article/10.3390/vaccines13030323/s1: Table S1: Influenza incidence, cases per 100,000 in Spain, 2013–2014; Table S2: Mortality; Table S3: Employment characteristics of the Spanish population, 2023; Table S4. Spanish population requiring care by a family member, 2008; Table S5: Tender price of the QIVe by region of Spain; Table S6: Summary of model scenarios used in the sensitivity analysis; Table S7: Summary of results from each model scenario in the sensitivity analysis.

Author Contributions

Conceptualization, J.M.-Q., A.P.-R., R.F., and J.R.A.; methodology, J.M.-Q., A.P.-R., R.F., and J.R.A. formal analysis, J.M.-Q., A.P.-R., R.F., and J.R.A.; investigation, J.M.-Q., A.P.-R., R.F., J.R.A., J.S., S.M.-P., P.A., and A.O.M.; writing—original draft preparation, J.M.-Q. and R.F.; writing—review and editing, J.M.-Q., A.P.-R., R.F., J.R.A., J.S., S.M.-P., P.A., and A.O.M.; funding acquisition, J.M.-Q. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by CSL Seqirus Inc. The findings and conclusions are those of the authors and do not necessarily represent the official position of CSL Seqirus.

Institutional Review Board Statement

This study was a retrospective study of de-identified secondary data and did not require ethical approval.

Informed Consent Statement

Patient consent was not required. This study was a retrospective study of de-identified secondary data.

Data Availability Statement

The original de-identified data used in this analysis were obtained from published sources. Interested researchers with reasonable and ethical inquiries may contact the authors for additional information.

Acknowledgments

Medical Consultant C. Gordon Beck and Amanda M. Justice provided medical writing and editorial support, which was funded by CSL Seqirus Inc.

Conflicts of Interest

Alberto Perez-Rubio, Jesus Ruiz Aragon, and Sergio Marquez-Peláez report investigator fees for this study funded by CSL Seqirus. Javier Sanchez, Piedad Alvarez, and Andres Osorio Muriel are employees of Evidera and received study funding from CSL Seqirus, Inc. Roberto Flores and Joaquin Mould-Quevedo are employees of CSL Seqirus, the funders of this study. Joaquin Mould-Quevedo holds CSL stock.

References

  1. World Health Organization. Influenza (Seasonal). Available online: https://www.who.int/news-room/fact-sheets/detail/influenza-(seasonal) (accessed on 13 September 2024).
  2. Centers for Disease Control and Prevention. Disease Burden of Flu. Available online: https://www.cdc.gov/flu-burden/php/about/index.html (accessed on 27 May 2024).
  3. Paget, J.; Spreeuwenberg, P.; Charu, V.; Taylor, R.J.; Iuliano, A.D.; Bresee, J.; Simonsen, L.; Viboud, C. Global mortality associated with seasonal influenza epidemics: New burden estimates and predictors from the GLaMOR Project. J. Glob. Health 2019, 9, 020421. [Google Scholar] [CrossRef]
  4. Iuliano, A.D.; Roguski, K.M.; Chang, H.H.; Muscatello, D.J.; Palekar, R.; Tempia, S.; Cohen, C.; Gran, J.M.; Schanzer, D.; Cowling, B.J.; et al. Estimates of global seasonal influenza-associated respiratory mortality: A modelling study. Lancet 2018, 391, 1285–1300. [Google Scholar] [CrossRef] [PubMed]
  5. Pérez-Rubio, A.; Platero, L.; Eiros Bouza, J.M. Seasonal influenza in Spain: Clinical and economic burden and vaccination programmes. Med. Clin. 2019, 153, 16–27. [Google Scholar] [CrossRef]
  6. Centers for Disease Control and Prevention (CDC). Estimated Influenza Illnesses, Medical Visits, Hospitalizations, and Deaths in the United States—2022–2023 Influenza Season. Available online: https://www.cdc.gov/flu-burden/php/data-vis/2022-2023.html (accessed on 29 August 2024).
  7. Mertz, D.; Kim, T.H.; Johnstone, J.; Lam, P.P.; Science, M.; Kuster, S.P.; Fadel, S.A.; Tran, D.; Fernandez, E.; Bhatnagar, N.; et al. Populations at risk for severe or complicated influenza illness: Systematic review and meta-analysis. BMJ 2013, 347, f5061. [Google Scholar] [CrossRef]
  8. Instituto de Salud Carlos III. Sistema de Vigilancia de la Gripe en España. Available online: https://vgripe.isciii.es/inicio.do (accessed on 22 May 2023).
  9. Oliva, J.; Delgado-Sanz, C.; Larrauri, A. Estimating the burden of seasonal influenza in Spain from surveillance of mild and severe influenza disease, 2010–2016. Influenza Other Respir. Viruses 2018, 12, 161–170. [Google Scholar] [CrossRef] [PubMed]
  10. Tokars, J.I.; Olsen, S.J.; Reed, C. Seasonal Incidence of Symptomatic Influenza in the United States. Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am. 2018, 66, 1511–1518. [Google Scholar] [CrossRef]
  11. Instituto Nacional de Estadistica. Ocupados por Sexo y Grupo de Edad. Valores Absolutos y Porcentajes Respecto del Total de Cada Sexo. Available online: https://www.ine.es/jaxiT3/Tabla.htm?t=4076&L=0 (accessed on 9 October 2024).
  12. de Courville, C.; Cadarette, S.M.; Wissinger, E.; Alvarez, F.P. The economic burden of influenza among adults aged 18 to 64: A systematic literature review. Influenza Other Respir. Viruses 2022, 16, 376–385. [Google Scholar] [CrossRef] [PubMed]
  13. GBD 2021 Risk Factors Collaborators. Global burden and strength of evidence for 88 risk factors in 204 countries and 811 subnational locations, 1990–2021: A systematic analysis for the Global Burden of Disease Study 2021. Lancet 2024, 403, 2162–2203. [Google Scholar] [CrossRef]
  14. National Foundation for Infectious Diseases. Call to Action: The Dangers of Influenza and Benefits of Vaccination in Adults with Chronic Health Conditions. Available online: https://www.nfid.org/resource/the-dangers-of-influenza-and-benefits-of-vaccination-in-adults-with-chronic-health-conditions-september-2018/ (accessed on 15 May 2023).
  15. Near, A.M.; Tse, J.; Young-Xu, Y.; Hong, D.K.; Reyes, C.M. Burden of influenza hospitalization among high-risk groups in the United States. BMC Health Serv. Res. 2022, 22, 1209. [Google Scholar] [CrossRef]
  16. MacNee, W.; Rabinovich, R.A.; Choudhury, G. Ageing and the border between health and disease. Eur. Respir. J. 2014, 44, 1332–1352. [Google Scholar] [CrossRef]
  17. Goodwin, K.; Viboud, C.; Simonsen, L. Antibody response to influenza vaccination in the elderly: A quantitative review. Vaccine 2006, 24, 1159–1169. [Google Scholar] [CrossRef]
  18. Weyand, C.M.; Goronzy, J.J. Aging of the Immune System. Mechanisms and Therapeutic Targets. Ann. Am. Thorac. Soc. 2016, 13 (Suppl. 5), S422–S428. [Google Scholar] [CrossRef] [PubMed]
  19. Ministerio de Sanidad Consumo y Bienestar Social. Recomendaciones de Vacunación Frente a Gripe y COVID-19 en la Temporada 2024–2025 en España. Available online: https://www.sanidad.gob.es/areas/promocionPrevencion/vacunaciones/gripe_covid19/docs/RecomendacionesVacunacion_Gripe-Covid19.pdf (accessed on 11 October 2024).
  20. Crooke, S.N.; Ovsyannikova, I.G.; Poland, G.A.; Kennedy, R.B. Immunosenescence: A systems-level overview of immune cell biology and strategies for improving vaccine responses. Exp. Gerontol. 2019, 124, 110632. [Google Scholar] [CrossRef] [PubMed]
  21. O’Hagan, D.T. MF59 is a safe and potent vaccine adjuvant that enhances protection against influenza virus infection. Expert. Rev. Vaccines 2007, 6, 699–710. [Google Scholar] [CrossRef]
  22. Frey, S.E.; Reyes, M.R.; Reynales, H.; Bermal, N.N.; Nicolay, U.; Narasimhan, V.; Forleo-Neto, E.; Arora, A.K. Comparison of the safety and immunogenicity of an MF59®-adjuvanted with a non-adjuvanted seasonal influenza vaccine in elderly subjects. Vaccine 2014, 32, 5027–5034. [Google Scholar] [CrossRef] [PubMed]
  23. Domnich, A.; Trombetta, C.S.; Fallani, E.; Salvatore, M. Immunogenicity and safety of the MF59-adjuvanted seasonal influenza vaccine in non-elderly adults: A systematic review and meta-analysis. PLoS ONE 2024, 19, e0310677. [Google Scholar] [CrossRef]
  24. DiazGranados, C.A.; Dunning, A.J.; Kimmel, M.; Kirby, D.; Treanor, J.; Collins, A.; Pollak, R.; Christoff, J.; Earl, J.; Landolfi, V.; et al. Efficacy of high-dose versus standard-dose influenza vaccine in older adults. N. Engl. J. Med. 2014, 371, 635–645. [Google Scholar] [CrossRef]
  25. López-Bastida, J.; Oliva, J.; Antoñanzas, F.; García-Altés, A.; Gisbert, R.; Mar, J.; Puig-Junoy, J. Spanish recommendations on economic evaluation of health technologies. Eur. J. Health Econ. 2010, 11, 513–520. [Google Scholar] [CrossRef]
  26. Ruiz-Aragón, J.; Gani, R.; Márquez, S.; Alvarez, P. Estimated cost-effectiveness and burden of disease associated with quadrivalent cell-based and egg-based influenza vaccines in Spain. Hum. Vaccines Immunother. 2020, 16, 2238–2244. [Google Scholar] [CrossRef]
  27. Jamotte, A.; Chong, C.F.; Manton, A.; Macabeo, B.; Toumi, M. Impact of quadrivalent influenza vaccine on public health and influenza-related costs in Australia. BMC Public Health 2016, 16, 630. [Google Scholar] [CrossRef]
  28. Uhart, M.; Bricout, H.; Clay, E.; Largeron, N. Public health and economic impact of seasonal influenza vaccination with quadrivalent influenza vaccines compared to trivalent influenza vaccines in Europe. Hum. Vaccines Immunother. 2016, 12, 2259–2268. [Google Scholar] [CrossRef] [PubMed]
  29. Reed, C.; Meltzer, M.I.; Finelli, L.; Fiore, A. Public health impact of including two lineages of influenza B in a quadrivalent seasonal influenza vaccine. Vaccine 2012, 30, 1993–1998. [Google Scholar] [CrossRef] [PubMed]
  30. Chit, A.; Roiz, J.; Aballea, S. An Assessment of the Expected Cost-Effectiveness of Quadrivalent Influenza Vaccines in Ontario, Canada Using a Static Model. PLoS ONE 2015, 10, e0133606. [Google Scholar] [CrossRef]
  31. Mennini, F.S.; Bini, C.; Marcellusi, A.; Rinaldi, A.; Franco, E. Cost-effectiveness of switching from trivalent to quadrivalent inactivated influenza vaccines for the at-risk population in Italy. Hum. Vaccines Immunother. 2018, 14, 1867–1873. [Google Scholar] [CrossRef]
  32. Ruiz-Aragón, J.; Márquez-Peláez, S.; Gani, R.; Alvarez, P.; Guerrero-Luduena, R. Cost-Effectiveness and Burden of Disease for Adjuvanted Quadrivalent Influenza Vaccines Compared to High-Dose Quadrivalent Influenza Vaccines in Elderly Patients in Spain. Vaccines 2022, 10, 176. [Google Scholar] [CrossRef] [PubMed]
  33. Ruiz-Aragón, J.; Márquez-Peláez, S. An Economic Comparison in the Elderly of Adjuvanted Quadrivalent Influenza Vaccine with Recombinant Quadrivalent Influenza Vaccine in Spain. Vaccines 2023, 11, 427. [Google Scholar] [CrossRef]
  34. Fochesato, A.; Sottile, S.; Pugliese, A.; Márquez-Peláez, S.; Toro-Diaz, H.; Gani, R.; Alvarez, P.; Ruiz-Aragón, J. An Economic Evaluation of the Adjuvanted Quadrivalent Influenza Vaccine Compared with Standard-Dose Quadrivalent Influenza Vaccine in the Spanish Older Adult Population. Vaccines 2022, 10, 1360. [Google Scholar] [CrossRef]
  35. Redondo, E.; Drago, G.; López-Belmonte, J.L.; Guillén, J.M.; Bricout, H.; Alvarez, F.P.; Callejo, D.; Gil de Miguel, Á. Cost-utility analysis of influenza vaccination in a population aged 65 years or older in Spain with a high-dose vaccine versus an adjuvanted vaccine. Vaccine 2021, 39, 5138–5145. [Google Scholar] [CrossRef]
  36. Instituto Nacional de Estadistica. Población Residente por Fecha, Sexo y Edad. Available online: https://www.ine.es/jaxiT3/Tabla.htm?t=59583&L=0 (accessed on 9 October 2024).
  37. Ministerio de Sanidad. Sistema de Información de Vacunaciones (SIVAMIN). Available online: https://pestadistico.inteligenciadegestion.sanidad.gob.es/publicoSNS/S/sivamin (accessed on 21 November 2024).
  38. Junta de Castilla de León. Seguimiento de las Coberturas de la Campaña de Vacunación Gripe y COVID-19 2023–2024. Available online: https://www.saludcastillayleon.es/profesionales/en/vacunaciones/campana-vacunacion-frente-gripe-covid-19-temporada-2023-202/seguimiento-coberturas-campana-vacunacion-gripe-covid-19-20 (accessed on 21 November 2024).
  39. Instituto de Salud Carlos III. Informe de Vigilancia de la Gripe en España. Temporada 2019–2020 (Desde la Semana 40/2019 Hasta la Semana 20/2020). Available online: https://vgripe.isciii.es/documentos/20192020/InformesAnuales/Informe_Vigilancia_GRIPE_2019-2020_03092020.pdf (accessed on 4 October 2024).
  40. Instituto de Salud Carlos III. Informe de Vigilancia de la Gripe en España. Temporada 2018–2019 (desde la Semana 40/2018 Hasta la Semana 20/2019). Available online: https://vgripe.isciii.es/documentos/20182019/InformesAnuales/Informe_Vigilancia_GRIPE_2018-2019_22julio2019.pdf (accessed on 4 October 2024).
  41. Instituto de Salud Carlos III. Informe de Vigilancia de la Gripe en España. Temporada 2016–2017 (Desde la Semana 40/2016 Hasta la Semana 20/2017). Available online: https://cne.isciii.es/documents/d/cne/vigilancia-de-la-gripe-en-espana-informe-temporada-2016-2017 (accessed on 4 October 2024).
  42. Instituto de Salud Carlos III. Informe de Vigilancia de la Gripe en España. Temporada 2017–2018 (Desde la Semana 40/2017 Hasta la Semana 20/2018). Available online: https://cne.isciii.es/documents/d/cne/vigilancia-de-la-gripe-en-espana-informe-temporada-2017-2018 (accessed on 4 October 2024).
  43. Instituto de Salud Carlos III. Informe de Vigilancia de la Gripe en España. Temporada 2015–2016 (Desde la Semana 40/2015 Hasta la Semana 20/2016). Available online: https://cne.isciii.es/documents/d/cne/vigilancia-de-la-gripe-en-espana-informe-temporada-2015-2016-pdf (accessed on 4 October 2024).
  44. Instituto de Salud Carlos III. Informe de Vigilancia de la Gripe en España. Temporada 2014–2015 (Desde la Semana 40/2014 Hasta la Semana 20/2015). Available online: https://cne.isciii.es/documents/d/cne/vigilancia-de-la-gripe-en-espana-informe-temporada-2014-2015-pdf (accessed on 4 October 2024).
  45. Delgado-Sanz, C.; Jiménez-Jorge, S.; Pozo, F.; Gómez-Barroso, D.; León-Gómez, I.; de Mateo, S.; Larrauri, A. Vigilancia de la gripe en Españ;a. Temporada 2013–2014 (Desde la Semana 40/2013 Hasta la Semana 20/2014). Boletín Epidemiol. Sem. 2014, 22, 146–166. [Google Scholar]
  46. León-Gómez, I.; Delgado-Sanz, C.; Jiménez-Jorge, S.; Flores, V.; Simón, F.; Gómez-Barroso, D.; Larrauri, A.; de Mateo Ontañón, S. Excess mortality associated with influenza in Spain in winter 2012. Gac Sanit 2015, 29, 258–265. [Google Scholar] [CrossRef]
  47. Ministerio de Sanidad Consumo y Bienestar Social. Acuerdo Marco para la Seleccion de Suministradores de Vacunas Frente a la Gripe Estacional (INGESA) y Ciudades de Ceuta y Melilla y Varias Comunidades Autonomas. Available online: https://contrataciondelestado.es/wps/wcm/connect/7c41cd41-00c8-4c07-be3d-272d29585268/DOC20210419131140PCAP+Gripe+2021-2025.pdf?MOD=AJPERES (accessed on 9 October 2024).
  48. Gobierno de La Rioja. Consulta Expedientes: Expediente nº.06-3-7.07-0019/2023—Adjudicación. Available online: https://www.larioja.org/contratacion-publica/es/licitaciones/consulta-expedientes?homepage=%3Fp_colateral%3D06-3-7.07-0019%2F2023%26p_dia_ini%3D28%26p_mes_ini%3D07%26p_ano_ini%3D2023%26p_dia_fin%3D28%26p_mes_fin%3D07%26p_ano_fin%3D2023%26p_todas%3DN (accessed on 4 December 2024).
  49. Gobierno de España. Plataforma de Contratacion del Sector Publico: Expediente: CS/9999/1101105289/23/PNSP. Available online: https://contrataciondelestado.es/wps/poc?uri=deeplink%3Adetalle_licitacion&idEvl=kHqM2iNSHV2ExvMJXBMHHQ%3D%3D (accessed on 4 December 2024).
  50. Gobierno del Principado de Asturias. Documentos Electrónicos Emitidos por el Principado de Asturias, Número de Referencia 14612415324201513343 [Login Required]. Available online: https://tramita.asturias.es/sta/CarpetaPublic/doEvent?APP_CODE=STA&PAGE_CODE=VALDOCS (accessed on 15 January 2025).
  51. Gobierno Vasco. Suministro de Vacunas Frente a la Gripe Estacional—Perfil de Contratante. Available online: https://www.contratacion.euskadi.eus/webkpe00-kpeperfi/es/contenidos/anuncio_contratacion/exposakisap2021000431/es_doc/index.html?ruta=informacionAmpliadaAnuncios&busquedaAvanzada (accessed on 4 December 2024).
  52. Gobierno de España. Plataforma de Contratacion del Sector Publico: Expediente: 181/2021/CMA. Available online: https://contrataciondelestado.es/wps/poc?uri=deeplink%3Adetalle_licitacion&idEvl=Q0aw7etnXBGmq21uxhbaVQ%3D%3D (accessed on 4 December 2024).
  53. Xunta de Galicia; Consellería de Sanidade. Datos Xerais. Available online: https://www.contratosdegalicia.gal/licitacion?OP=50&N=819632&lang=gl (accessed on 4 December 2024).
  54. Gobierno de España. Plataforma de Contratacion del Sector Publico: Expediente: CS/99/1123044902/23/PNSP. Available online: https://contrataciondelestado.es/wps/poc?uri=deeplink%3Adetalle_licitacion&idEvl=HopD%2BsAA%2FDk4NavIWzMcHA%3D%3D (accessed on 4 December 2024).
  55. Gobierno de España. Plataforma de Contratacion del Sector Publico: Expediente: 725/2021 Tercer Basado Lote1. Available online: https://contrataciondelestado.es/wps/poc?uri=deeplink%3Adetalle_licitacion&idEvl=LDBtSC1j%2B%2BHua%2Fi14w%2FPLA%3D%3D (accessed on 4 December 2024).
  56. Gobierno de Navarra. Comprobación de Documentos Marcados con un Código Seguro de Verificación (CSV) [Verification of Documents Marked with a Secure Verification Code]. Available online: https://www.navarra.es/es/tramites/on/-/line/Comprobacion-de-documentos-marcados-con-un-codigo-seguro-de-verificacion-CSV (accessed on 4 December 2024).
  57. Comunidad de Madrid. Contratos Basados en el Acuerdo Marco 202101AM0001, Relativo al Suministro de Vacunas Frente a la Gripe Estacional, 2 Lotes (lote 1 y lote 3) Para la Campaña de Vacunación Antigripal de la Temporada 2023–2024 Para la Comunidad de Madrid. Available online: https://contratos-publicos.comunidad.madrid/contrato-publico/contratos-basados-acuerdo-marco-202101am0001-relativo-suministro-vacunas-frente (accessed on 4 December 2024).
  58. Gobierno de España. Plataforma de Contratacion del Sector Publico: Expediente: 19251/23. Available online: https://contrataciondelestado.es/wps/poc?uri=deeplink%3Adetalle_licitacion&idEvl=EjOGS%2BYgL0rzAq95uGTrDQ%3D%3D (accessed on 4 December 2024).
  59. Catalunya, G.D. Plataforma de Serveis de Contractació Pública: Adquisició de Vacunes per a L’any 2023 (SA-2023-39). Available online: https://contractaciopublica.cat/es/detall-publicacio/200156331 (accessed on 4 December 2024).
  60. Gobierno de España. Plataforma de Contratacion del Sector Publico: Expediente: 182/2023. Available online: https://contrataciondelestado.es/wps/poc?uri=deeplink%3Adetalle_licitacion&idEvl=pmcEYn4kqsVPpzdqOdhuWg%3D%3D (accessed on 4 December 2024).
  61. Gobierno de España. Plataforma de Contratacion del Sector Publico: Expediente: SAS-SGE-2023-42. Available online: https://contrataciondelestado.es/wps/poc?uri=deeplink:detalle_licitacion&idEvl=st4PYafAE6geC9GJQOEBkQ%3D%3D (accessed on 2 December 2024).
  62. Gobierno de España. Plataforma de Contratacion del Sector Publico: Expediente: 2021/ETSAE0287/00000463E. Available online: https://contrataciondelestado.es/wps/poc?uri=deeplink%3Adetalle_licitacion&idEvl=i%2Bv38mJHKLnnSoTX3z%2F7wA%3D%3D (accessed on 4 December 2024).
  63. Gobierno de España. Plataforma de Contratacion del Sector Publico: Expediente: PRO11 2023 12880. Available online: https://contrataciondelestado.es/wps/poc?uri=deeplink%3Adetalle_licitacion&idEvl=OBymDxcgIdKopEMYCmrbmw%3D%3D (accessed on 2 December 2024).
  64. Gobierno de España. Plataforma de Contratacion del Sector Publico: Expediente: 02/CONS/DGSP/2023. Available online: https://contrataciondelestado.es/wps/poc?uri=deeplink%3Adetalle_licitacion&idEvl=Uh9akaL3pAY%2Bk2oCbDosIw%3D%3D (accessed on 4 December 2024).
  65. Gobierno de España. Plataforma de Contratacion del Sector Publico: Expediente: 10.2.10/23. Available online: https://contrataciondelestado.es/wps/poc?uri=deeplink%3Adetalle_licitacion&idEvl=%2FWwhozokA5q5HQrHoP3G5A%3D%3D (accessed on 4 December 2024).
  66. Gobierno de España. Plataforma de Contratacion del Sector Publico: Expediente: 2023/007980. Available online: https://contrataciondelestado.es/wps/poc?uri=deeplink%3Adetalle_licitacion&idEvl=Iu2C4QH969fyoM4us5k4vw%3D%3D (accessed on 4 December 2024).
  67. Junta de Andalucía. CCA:+6.+PJ7JD7 Acuerdo Marco Con Una Única Empresa por Lote, por el que se Fijan las Condiciones Para el Suministro de Tracto Sucesivo y Precio Unitario de Vacuna Antigripal Destinada al Programa de Vacunaciones de Andalucía, Campaña 2023–2024. Available online: https://www.juntadeandalucia.es/haciendayadministracionpublica/apl/pdc_sirec/perfiles-licitaciones/detalle-licitacion.jsf?idExpediente=531651 (accessed on 4 December 2024).
  68. Osakidetza. Tarifas Para Facturacion de Servicios Sanitarios y Docentes de Osakidetza 2024. Available online: https://www.osakidetza.euskadi.eus/contenidos/informacion/osk_servic_para_empresas/es_def/adjuntos/LIBRO-DE-TARIFAS-2024-CAS_V2.pdf (accessed on 11 March 2025).
  69. Ministerio de Sanidad. Registro de Altas de los Hospitales Generales del Sistema Nacional de Salud. CMBD. Norma Estatal. Resultados Según la Versión 38 de los APR-GRD. Available online: https://www.sanidad.gob.es/estadEstudios/estadisticas/cmbd.htm (accessed on 9 October 2024).
  70. Region de Murcia; Consejeria de Hacienda y Administracion Publica. Boletin Oficial de la Region de Murcia. Available online: https://www.borm.es/services/boletin/ano/2022/numero/94/pdf (accessed on 9 October 2024).
  71. Ehlken, B.; Anastassopoulou, A.; Hain, J.; Schröder, C.; Wahle, K. Cost for physician-diagnosed influenza and influenza-like illnesses on primary care level in Germany—Results of a database analysis from May 2010 to April 2012. BMC Public Health 2015, 15, 578. [Google Scholar] [CrossRef] [PubMed]
  72. Ramos-Rincón, J.M.; Pinargote-Celorio, H.; González-de-la-Aleja, P.; Sánchez-Payá, J.; Reus, S.; Rodríguez-Díaz, J.C.; Merino, E. Impact of influenza related hospitalization in Spain: Characteristics and risk factor of mortality during five influenza seasons (2016 to 2021). Front. Public Health 2024, 12, 1360372. [Google Scholar] [CrossRef]
  73. Instituto Nacional de Estadistica. Encuesta de Discapacidad, Autonomía Personal y Situaciones de Dependencia 2008: Discapacidades, Deficiencias y Estado de Salud. Resultados Nacionales: Cifras Relativas. Tasa de Población con Alguna Discapacidad o Limitación por Edad y Sexo. Available online: https://www.ine.es/jaxi/Tabla.htm?path=/t15/p418/a2008/hogares/p01/modulo1/l0/&file=02001.px&L=0 (accessed on 9 October 2024).
  74. Instituto Nacional de Estadistica. Resultado por Comunidades Autónomas (Desde el Trimestre 1/2008). Componentes del Coste Laboral Total. Available online: https://www.ine.es/jaxiT3/Tabla.htm?t=6062 (accessed on 12 November 2024).
  75. García, A.; Ortiz de Lejarazu, R.; Reina, J.; Callejo, D.; Cuervo, J.; Morano Larragueta, R. Cost-effectiveness analysis of quadrivalent influenza vaccine in Spain. Hum. Vaccines Immunother. 2016, 12, 2269–2277. [Google Scholar] [CrossRef] [PubMed]
  76. Dolk, C.; Eichner, M.; Welte, R.; Anastassopoulou, A.; Van Bellinghen, L.A.; Poulsen Nautrup, B.; Van Vlaenderen, I.; Schmidt-Ott, R.; Schwehm, M.; Postma, M. Cost-Utility of Quadrivalent Versus Trivalent Influenza Vaccine in Germany, Using an Individual-Based Dynamic Transmission Model. PharmacoEconomics 2016, 34, 1299–1308. [Google Scholar] [CrossRef]
  77. Hollmann, M.; Garin, O.; Galante, M.; Ferrer, M.; Dominguez, A.; Alonso, J. Impact of influenza on health-related quality of life among confirmed (H1N1)2009 patients. PLoS ONE 2013, 8, e60477. [Google Scholar] [CrossRef] [PubMed]
  78. Domnich, A.; de Waure, C. Comparative effectiveness of adjuvanted versus high-dose seasonal influenza vaccines for older adults: A systematic review and meta-analysis. Int. J. Infect. Dis. 2022, 122, 855–863. [Google Scholar] [CrossRef]
  79. Boikos, C.; Sylvester, G.C.; Sampalis, J.S.; Mansi, J.A. Relative effectiveness of the cell-cultured quadrivalent influenza vaccine compared to standard, egg-derived quadrivalent influenza vaccines in preventing influenza-like illness in 2017–2018. Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am. 2020, 71, e665–e671. [Google Scholar] [CrossRef]
  80. Boikos, C.; Fischer, L.; O’Brien, D.; Vasey, J.; Sylvester, G.C.; Mansi, J.A. Relative Effectiveness of the Cell-derived Inactivated Quadrivalent Influenza Vaccine Versus Egg-derived Inactivated Quadrivalent Influenza Vaccines in Preventing Influenza-related Medical Encounters During the 2018–2019 Influenza Season in the United States. Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am. 2021, 73, e692–e698. [Google Scholar] [CrossRef]
  81. Imran, M.; Ortiz, J.R.; McLean, H.Q.; Fisher, L.; O’Brien, D.; Bonafede, M.; Mansi, J.A.; Boikos, C. Relative Effectiveness of Cell-based Versus Egg-based Quadrivalent Influenza Vaccines in Children and Adolescents in the United States During the 2019-2020 Influenza Season. Pediatr. Infect. Dis. J. 2022, 41, 769–774. [Google Scholar] [CrossRef]
  82. Divino, V.; Ruthwik Anupindi, V.; DeKoven, M.; Mould-Quevedo, J.; Pelton, S.I.; Postma, M.J.; Levin, M.J. A Real-World Clinical and Economic Analysis of Cell-Derived Quadrivalent Influenza Vaccine Compared to Standard Egg-Derived Quadrivalent Influenza Vaccines During the 2019–2020 Influenza Season in the United States. Open Forum Infect. Dis. 2022, 9, ofab604. [Google Scholar] [CrossRef]
  83. Divino, V.; Krishnarajah, G.; Pelton, S.I.; Mould-Quevedo, J.; Anupindi, V.R.; DeKoven, M.; Postma, M.J. A real-world study evaluating the relative vaccine effectiveness of a cell-based quadrivalent influenza vaccine compared to egg-based quadrivalent influenza vaccine in the US during the 2017–18 influenza season. Vaccine 2020, 38, 6334–6343. [Google Scholar] [CrossRef]
  84. Krishnarajah, G.; Divino, V.; Postma, M.J.; Pelton, S.I.; Anupindi, V.R.; DeKoven, M.; Mould-Quevedo, J. Clinical and Economic Outcomes Associated with Cell-Based Quadrivalent Influenza Vaccine vs. Standard-Dose Egg-Based Quadrivalent Influenza Vaccines during the 2018–19 Influenza Season in the United States. Vaccines 2021, 9, 80. [Google Scholar] [CrossRef] [PubMed]
  85. Imran, M.; Ortiz, J.R.; McLean, H.Q.; Fisher, L.; O’Brien, D.; Bonafede, M.; Mansi, J.A.; Boikos, C. Relative Effectiveness of Cell-Based Versus Egg-Based Quadrivalent Influenza Vaccines in Adults During the 2019-2020 Influenza Season in the United States. Open Forum Infect. Dis. 2022, 9, ofac532. [Google Scholar] [CrossRef]
  86. Stein, A.N.; Mills, C.W.; McGovern, I.; McDermott, K.W.; Dean, A.; Bogdanov, A.N.; Sullivan, S.G.; Haag, M.D.M. Relative Vaccine Effectiveness of Cell- vs Egg-Based Quadrivalent Influenza Vaccine Against Test-Confirmed Influenza Over 3 Seasons Between 2017 and 2020 in the United States. Open Forum Infect. Dis. 2024, 11, ofae175. [Google Scholar] [CrossRef] [PubMed]
  87. Hsiao, A.; Yee, A.; Leong, T.; Zerbo, O.; Fireman, B.; Jacobson, K.; Hansen, J.; Layefsky, E.; Haag, M.; McGovern, I.; et al. Effectiveness of adjuvanted inactivated influenza vaccine versus high-dose inactivated influenza vaccine against PCR-confirmed influenza among adults ≥ 65 years: A pragmatic randomized study. In Proceedings of the ID Week 2024, Los Angeles, CA, USA, 16–19 October 2024. [Google Scholar]
  88. McConeghy, K.W.; Davidson, H.E.; Canaday, D.H.; Han, L.; Saade, E.; Mor, V.; Gravenstein, S. Cluster-randomized Trial of Adjuvanted Versus Nonadjuvanted Trivalent Influenza Vaccine in 823 US Nursing Homes. Clin. Infect. Dis. 2021, 73, e4237–e4243. [Google Scholar] [CrossRef]
  89. Vallejo-Torres, L.; García-Lorenzo, B.; Serrano-Aguilar, P. Estimating a cost-effectiveness threshold for the Spanish NHS. Health Econ. 2018, 27, 746–761. [Google Scholar] [CrossRef] [PubMed]
  90. Sacristán, J.A.; Oliva, J.; Campillo-Artero, C.; Puig-Junoy, J.; Pinto-Prades, J.L.; Dilla, T.; Rubio-Terrés, C.; Ortún, V. What is an efficient health intervention in Spain in 2020? Gac Sanit 2020, 34, 189–193. [Google Scholar] [CrossRef]
  91. Coleman, B.L.; Sanderson, R.; Haag, M.D.M.; McGovern, I. Effectiveness of the MF59-adjuvanted trivalent or quadrivalent seasonal influenza vaccine among adults 65 years of age or older, a systematic review and meta-analysis. Influenza Other Respir. Viruses 2021, 15, 813–823. [Google Scholar] [CrossRef]
  92. Calabrò, G.E.; Boccalini, S.; Bonanni, P.; Bechini, A.; Panatto, D.; Lai, P.L.; Amicizia, D.; Rizzo, C.; Ajelli, M.; Trentini, F. Valutazione di Health Technology Assessment (HTA) del Vaccino Antinfluenzale Quadrivalente Adiuvato: Fluad Tetra. Available online: https://www.ijph.it/hta-vaccino-antinfluenzale-quadrivalente-adiuvato-fluad-tetra (accessed on 23 May 2023).
  93. Aballéa, S.; De Juanes, J.R.; Barbieri, M.; Martin, M.; Chancellor, J.; Oyagüez, I.; Verwee, B.; Largeron, N. The cost effectiveness of influenza vaccination for adults aged 50 to 64 years: A model-based analysis for Spain. Vaccine 2007, 25, 6900–6910. [Google Scholar] [CrossRef]
  94. Maciosek, M.V.; Solberg, L.I.; Coffield, A.B.; Edwards, N.M.; Goodman, M.J. Influenza vaccination health impact and cost effectiveness among adults aged 50 to 64 and 65 and older. Am. J. Prev. Med. 2006, 31, 72–79. [Google Scholar] [CrossRef]
  95. Kohli, M.A.; Maschio, M.; Mould-Quevedo, J.F.; Ashraf, M.; Drummond, M.F.; Weinstein, M.C. The Cost-Effectiveness of Expanding Vaccination with a Cell-Based Influenza Vaccine to Low Risk Adults Aged 50 to 64 Years in the United Kingdom. Vaccines 2021, 9, 598. [Google Scholar] [CrossRef] [PubMed]
  96. Nguyen, V.H.; Ashraf, M.; Mould-Quevedo, J.F. Estimating the impact of influenza vaccination of low-risk 50–64-year-olds on acute and ICU hospital bed usage in an influenza season under endemic COVID-19 in the UK. Hum. Vaccines Immunother. 2023, 19, 2187592. [Google Scholar] [CrossRef] [PubMed]
  97. Marchi, S.; Fallani, E.; Salvatore, M.; Montomoli, E.; Trombetta, C.M. The burden of influenza and the role of influenza vaccination in adults aged 50–64 years: A summary of available evidence. Hum. Vaccines Immunother. 2023, 19, 2257048. [Google Scholar] [CrossRef] [PubMed]
  98. Ruiz-Aragón, J.; Grande Tejada, A.M.; Márquez-Peláez, S.; García-Cenoz, M. Estimación del impacto de la vacunación antigripal con adyuvante MF59 en población mayor de 64 años para el Sistema Nacional de Salud: Efectos y costes. Vacunas 2015, 16, 6–11. [Google Scholar] [CrossRef]
  99. Pérez-Rubio, A.; Eiros, J.M. Economic and Health impact of influenza vaccination with adjuvant MF59 in population over 64 years in Spain. Rev. Esp. Quim. 2018, 31, 43–52. [Google Scholar]
  100. Lee, J.K.H.; Lam, G.K.L.; Shin, T.; Kim, J.; Krishnan, A.; Greenberg, D.P.; Chit, A. Efficacy and effectiveness of high-dose versus standard-dose influenza vaccination for older adults: A systematic review and meta-analysis. Expert. Rev. Vaccines 2018, 17, 435–443. [Google Scholar] [CrossRef]
  101. Puig-Barberà, J.; Natividad-Sancho, A.; Calabuig-Pérez, J.; Lluch-Rodrigo, J.A.; Pastor-Villalba, E.; Martínez-Úbeda, S.; Pérez-Vilar, S.; Díez-Domingo, J. MF59-adjuvanted and virosomal influenza vaccines for preventing influenza hospitalization in older people: Comparative effectiveness using the Valencia health care information system. Vaccine 2013, 31, 3995–4002. [Google Scholar] [CrossRef]
  102. Ferdinands, J.M.; Blanton, L.H.; Alyanak, E.; Chung, J.R.; Trujillo, L.; Taliano, J.; Morgan, R.L.; Fry, A.M.; Grohskopf, L.A. Protection against influenza hospitalizations from enhanced influenza vaccines among older adults: A systematic review and network meta-analysis. J. Am. Geriatr. Soc. 2024, 72, 3875–3889. [Google Scholar]
  103. Paget, J.; Caini, S.; Del Riccio, M.; van Waarden, W.; Meijer, A. Has influenza B/Yamagata become extinct and what implications might this have for quadrivalent influenza vaccines? Euro Surveill. Bull. Eur. Sur Les. Mal. Transm. Eur. Commun. Dis. Bull. 2022, 27, 29. [Google Scholar] [CrossRef]
Vaccines 13 00323 g001
Figure 1. Schematic of the health economic model. ED, emergency department; LY, life years; QALY, quality-adjusted life year. Adapted from Ruiz-Aragón et al. Vaccines (Basel). 2022; 10:176 [32].
Figure 1. Schematic of the health economic model. ED, emergency department; LY, life years; QALY, quality-adjusted life year. Adapted from Ruiz-Aragón et al. Vaccines (Basel). 2022; 10:176 [32].
Vaccines 13 00323 g001
Vaccines 13 00323 g002
Figure 2. Results of the probabilistic sensitivity analysis (PSA) in persons at high risk of influenza complications. aQIV, adjuvanted quadrivalent influenza vaccine; HD-QIV, high-dose quadrivalent influenza vaccine; QALY, quality-adjusted life year; QIVe, egg-based quadrivalent influenza vaccine.
Figure 2. Results of the probabilistic sensitivity analysis (PSA) in persons at high risk of influenza complications. aQIV, adjuvanted quadrivalent influenza vaccine; HD-QIV, high-dose quadrivalent influenza vaccine; QALY, quality-adjusted life year; QIVe, egg-based quadrivalent influenza vaccine.
Vaccines 13 00323 g002
Vaccines 13 00323 g003
Figure 3. Cost-effectiveness acceptability curve comparing the probability of being the most cost-effective option between the aQIV (intervention) and control, i.e., either the QIVe given to persons aged 50–59 years who are at high risk of influenza complications or the HD-QIV administered to persons aged ≥60 years. aQIV, adjuvanted quadrivalent influenza vaccine; HD-QIV, high-dose quadrivalent influenza vaccine; QALY, quality-adjusted life year; QIVe, egg-based quadrivalent influenza vaccine.
Figure 3. Cost-effectiveness acceptability curve comparing the probability of being the most cost-effective option between the aQIV (intervention) and control, i.e., either the QIVe given to persons aged 50–59 years who are at high risk of influenza complications or the HD-QIV administered to persons aged ≥60 years. aQIV, adjuvanted quadrivalent influenza vaccine; HD-QIV, high-dose quadrivalent influenza vaccine; QALY, quality-adjusted life year; QIVe, egg-based quadrivalent influenza vaccine.
Vaccines 13 00323 g003
Vaccines 13 00323 g004
Figure 4. Tornado diagram showing the incremental net monetary benefit for the aQIV vs. the QIVe (age 50–59 years at high risk of influenza complications) or the HD-QIV (age ≥60 years) at a willingness-to-pay threshold of EUR 25,000 per QALY. aQIV, adjuvanted quadrivalent influenza vaccine; HD-QIV, high-dose quadrivalent influenza vaccine; QIVe, egg-based quadrivalent influenza vaccine; rVE, relative vaccine effectiveness.
Figure 4. Tornado diagram showing the incremental net monetary benefit for the aQIV vs. the QIVe (age 50–59 years at high risk of influenza complications) or the HD-QIV (age ≥60 years) at a willingness-to-pay threshold of EUR 25,000 per QALY. aQIV, adjuvanted quadrivalent influenza vaccine; HD-QIV, high-dose quadrivalent influenza vaccine; QIVe, egg-based quadrivalent influenza vaccine; rVE, relative vaccine effectiveness.
Vaccines 13 00323 g004
Table 1. Characteristics of the population analyzed in the model [36,37,38].
Table 1. Characteristics of the population analyzed in the model [36,37,38].
Age GroupTotal Population
N		Life Expectancy
Years		High Risk
n (%)		Low Risk
n (%)		Influenza Vaccine Coverage, High Risk
%
50–59 years7,475,39730.64,770,798 (63.8)2,704,599 (36.2)24.54%
60–64 years3,214,01223.63,214,012 (100)036.72%
65–74 years4,974,17517.94,974,175 (100)061.57%
≥75 years4,890,7666.44,890,766 (100)075.27%
Table 2. Model inputs.
Table 2. Model inputs.
ParameterValueReference
aQIV tender priceEUR 13[47]
QIVe tender price aEUR 4.78[48,49,50,51,52,53,54,55,56,57,58,59,60,61,62,63,64,65,66,67]
HD-QIV tender priceEUR 25[47]
Primary care physician visit costs (per visit)EUR 65.00[68]
ED visit costs (per visit)EUR 257.00[68]
Hospitalization costs (per event)EUR 5809.61[69]
Nurse consultation costEUR 25.94[70]
No. business days of disabilityPrimary care physician visit5[71]
ED visit5[71]
Hospitalization15 b[72]
Employment rate0–50 years65.8%[11]
50–59 years71.6%[11]
60–64 years48.9%[11]
65–74 years10.0%[11]
≥75 years0.8%[11]
Proportion requiring care at home65–74 years18.4%[73]
≥75 years45.1%[73]
Proportion aged 18–64 who care for a family member and are also employed35.15%[73]
Productivity loss per day c0–50 yearsEUR 106.58[74]
50–59 yearsEUR 126.86[74]
60–64 yearsEUR 129.78[74]
65–74 yearsEUR 129.78[74]
≥75 yearsEUR 129.78[74]
Baseline utilityHigh riskLow risk
0–50 years0.9400.975[75]
50–59 years0.8700.960[75]
60–64 years0.8700.960[75]
65–74 years0.8360.955[75]
≥75 years0.6760.836[75]
Disutility value for symptomatic patients (all ages)0.32[76]
Disutility value for outpatient and ED settingsHigh riskLow risk
0–50 years0.420.40[77]
50–59 years0.420.40[77]
60–64 years0.460.44[77]
65–74 years0.370.35[77]
≥75 years0.33—[77]
Disutility value for an inpatient setting (all ages)0.420.40[77]
Disutility duration for symptomatic patients7 days[76]
Disutility duration in an outpatient setting7 days[77]
Disutility duration in an inpatient setting7 days[77]
Discount rate for costs and outcomes d3%[25]
aQIV, adjuvanted quadrivalent influenza vaccine; ED, emergency department; HD-QIV, high-dose quadrivalent influenza vaccine; QALY, quality-adjusted life year; QIVe, egg-based, standard-dose influenza vaccine. a Weighted average of tender prices across Spanish regions. b Equivalent to the QALY loss for 3 weeks. c Productivity loss per day is calculated as the labor cost per hour (EUR 16.22) times daily labor hours (8 h). d Productivity loss due to death and quality-adjusted life year loss due to death are calculated over a lifetime horizon and discounted at 3% per year.
Table 3. Costs of influenza vaccines and vaccine administration in persons at high risk of influenza complications aged ≥50 years in Spain.
Table 3. Costs of influenza vaccines and vaccine administration in persons at high risk of influenza complications aged ≥50 years in Spain.
Current Scenario aAlternative Scenario a
CostsAge GroupNumber VaccinatedQIVeHD-QIV(aQIV)Incremental Difference
Influenza vaccines50–59 years1,170,754EUR 5,596,204EUR 15,219,801EUR 9,623,597
60–64 years1,180,185EUR 29,504,630EUR 15,342,408EUR −14,162,222
65–74 years3,062,600EUR 76,564,989EUR 39,813,794EUR −36,751,195
≥75 years3,681,280EUR 92,031,989EUR 47,856,634EUR −44,175,355
Total b9,094,819EUR 203,697,812EUR 118,232,637EUR −85,465,175
Vaccine administration50–59 years1,170,754EUR 30,369,357EUR 30,369,357EUR 0
60–64 years1,180,185EUR 30,614,004EUR 30,614,004EUR 0
65–74 years3,062,600EUR 79,443,832EUR 79,443,832EUR 0
≥75 years3,681,280EUR 95,492,392EUR 95,492,392EUR 0
Total b9,094,819EUR 235,919,585EUR 235,919,585EUR 0
aQIV, adjuvanted quadrivalent influenza vaccine; HD-QIV, high-dose quadrivalent influenza vaccine; QIVe, egg-based quadrivalent influenza vaccine. a In the current scenario of the model, persons were vaccinated according to age-based indication, i.e., the QIVe for those aged 50–59 years and the HD-QIV for those aged ≥60 years. In the alternative scenario, all persons aged ≥50 years were vaccinated with the aQIV. b Total for the current scenario includes both QIVe and HD-QIV costs.
Table 4. Comparative clinical outcomes and cost analyses.
Table 4. Comparative clinical outcomes and cost analyses.
ParameterCurrent Scenario a
(QIVe or HD-QIV)		Alternative Scenario a
(aQIV)		DifferenceCurrent Scenario a
(QIVe or HD-QIV)		Alternative Scenario a
(aQIV)		Difference
Clinical outcomesQALY per vaccination
QALY loss21,19120,950−2410.002330.00230−0.00003
Life years lost31,06030,742−3180.003420.00338−0.00003
EventsEvents per vaccination
Symptomatic influenza cases165,050162,151−28991.815%1.783%−0.00032
Primary care visits107,884106,171−17131.186%1.167%−0.00019
ED visits24,21323,829−3840.266%0.262%−0.00004
Hospitalizations15,06414,907−1570.166%0.164%−0.00002
Deaths38953860−350.043%0.042%0.00000
CostsCosts per vaccination
Primary care visitsEUR 7,358,761EUR 7,241,929EUR −116,832EUR 0.8091EUR 0.7963EUR −0.013
ED visitsEUR 6,222,855EUR 6,124,057EUR −98,798EUR 0.6842EUR 0.6734EUR −0.011
HospitalizationsEUR 87,514,956EUR 86,603,793EUR −911,163EUR 9.6225EUR 9.5223EUR −0.100
VaccinationEUR 439,617,397EUR 354,152,222EUR −85,465,175EUR 48.3371EUR 38.9400EUR −9.397
TotalEUR 540,713,969EUR 454,122,002EUR −86,591,968EUR 59.4530EUR 49.9319EUR −9.521
aQIV, adjuvanted quadrivalent influenza vaccine; HD-QIV, high-dose quadrivalent vaccine; ED, emergency department; QALY, quality-adjusted life year; QIVe, egg-based quadrivalent vaccine. a In the current scenario of the model, persons were vaccinated according to age-based indication, i.e., the QIVe for those aged 50–59 years and the HD-QIV for those aged ≥60 years. In the alternative scenario, all persons aged ≥50 years were vaccinated with the aQIV.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Perez-Rubio, A.; Flores, R.; Aragon, J.R.; Sanchez, J.; Marquez-Peláez, S.; Alvarez, P.; Muriel, A.O.; Mould-Quevedo, J. Cost-Effectiveness of Adjuvanted Influenza Vaccine Compared with Standard and High-Dose Influenza Vaccines for Persons Aged ≥50 Years in Spain. Vaccines 2025, 13, 323. https://doi.org/10.3390/vaccines13030323

AMA Style

Perez-Rubio A, Flores R, Aragon JR, Sanchez J, Marquez-Peláez S, Alvarez P, Muriel AO, Mould-Quevedo J. Cost-Effectiveness of Adjuvanted Influenza Vaccine Compared with Standard and High-Dose Influenza Vaccines for Persons Aged ≥50 Years in Spain. Vaccines. 2025; 13(3):323. https://doi.org/10.3390/vaccines13030323

Chicago/Turabian Style

Perez-Rubio, Alberto, Roberto Flores, Jesus Ruiz Aragon, Javier Sanchez, Sergio Marquez-Peláez, Piedad Alvarez, Andres Osorio Muriel, and Joaquin Mould-Quevedo. 2025. "Cost-Effectiveness of Adjuvanted Influenza Vaccine Compared with Standard and High-Dose Influenza Vaccines for Persons Aged ≥50 Years in Spain" Vaccines 13, no. 3: 323. https://doi.org/10.3390/vaccines13030323

APA Style

Perez-Rubio, A., Flores, R., Aragon, J. R., Sanchez, J., Marquez-Peláez, S., Alvarez, P., Muriel, A. O., & Mould-Quevedo, J. (2025). Cost-Effectiveness of Adjuvanted Influenza Vaccine Compared with Standard and High-Dose Influenza Vaccines for Persons Aged ≥50 Years in Spain. Vaccines, 13(3), 323. https://doi.org/10.3390/vaccines13030323

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop